Agents targeting the VEGF pathway have shown potential in preclinical and clinical models to normalize tumor vasculature, reduce edema, enhance tissue oxygenation, and improve the efficacy of RT, chemotherapy, or immunotherapy [37, 38]. This evidence concerns the gene VEGFA and neoplasm.